Abbisko Cayman Limited

2256

KYG0028A1085

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 01:38:25 2024-04-25 am EDT			5-day change	1st Jan Change
3.11 ^HKD	0.00%		+8.74%	-14.79%

Apr. 24	Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	CI
Apr. 10	Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	MT

Abbisko Cayman Limited(SEHK:2256) added to S&P Global BMI Index

March 21, 2022 at 12:00 am EDT

Latest news about Abbisko Cayman Limited

Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	Apr. 24	CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	Apr. 09	MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	Apr. 08	MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	Apr. 08	CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	Mar. 14	MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	Mar. 13	MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	Mar. 12	CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	Feb. 22	MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	Feb. 05	MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	Feb. 02	MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	Jan. 09	MT
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	Jan. 03	MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	Jan. 02	CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	Dec. 13	MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	Dec. 13	CI
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	Nov. 27	MT
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	Nov. 27	CI
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug	Nov. 09	MT
Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051	Nov. 08	CI
US FDA Green Lights Abbisko Subsidiary's Phase 1 Study for Anti-Tumor Drug	Nov. 07	MT
Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting	Nov. 06	CI
Abbisko Cayman Presents Clinical Trial Results of Tenosynovial Giant Cell Tumor Drug at Ireland Meeting	Nov. 02	MT
Abbisko Cayman Unit to Present Data on Tenosynovial Giant Cell Tumor Drug at Conference; Shares Rise 10%	23-10-29	MT
China Grants Clinical Study Approval for Abbisko Cayman Unit's Anti-Tumor Drug	23-10-27	MT

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâs products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Abbisko Cayman Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.877 CNY

Average target price

7.572 CNY

Spread / Average Target

+163.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABBISKO CAYMAN LIMITED	-14.79%	232M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs